‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

In 2026, biotech mergers and acquisitions are experiencing a surge, marking the best year since before the Covid pandemic. The driving forces behind this trend include the impending expiration of numerous patents, a rebound in public market confidence, and Big Pharma's aggressive push to bolster their drug pipelines. This wave of deals not only highlights the industry's strategic pivot but also suggests significant implications for innovation and competition in the biotech sector. The influx of investment and strategic partnerships could lead to groundbreaking advancements and reshape the future landscape of pharmaceutical development.